Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 18/20 | 1.00 |
| ▸ | PIK3CA | P42336 | 17/20 | 1.00 |
| ▸ | MAPK8 | P45983 | 16/20 | 1.00 |
| ▸ | MAPK9 | P45984 | 16/20 | 1.00 |
| ▸ | MAPK10 | P53779 | 16/20 | 1.00 |
| ▸ | YES1 | P07947 | 1/20 | 0.61 |
| ▸ | HIPK1 | Q86Z02 | 1/20 | 0.61 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4344709 | 0.94 | PIK3CA (0.88) | MAPK1PIK3CAMAPK8MAPK9MAPK10 | |
| SCHEMBL5447864 | 0.92 | MAPK1 (1.00) | MAPK1PIK3CAMAPK8MAPK9MAPK10 | |
| SCHEMBL4668826 | 0.91 | MAPK1 (0.82) | MAPK1PIK3CAMAPK8MAPK9MAPK10 | |
| SCHEMBL4349645 | 0.87 | MAPK1 (0.87) | MAPK1PIK3CAMAPK8MAPK9MAPK10 | |
| SCHEMBL4353812 | 0.86 | MAPK1 (0.86) | MAPK1PIK3CAMAPK8MAPK9MAPK10 | |
| SCHEMBL14506784 | 0.86 | MAPK1 (0.85) | MAPK1PIK3CAMAPK8MAPK9MAPK10 | |
| SCHEMBL4341731 | 0.86 | PIK3CA (0.85) | MAPK1PIK3CAMAPK8MAPK9MAPK10 | |
| SCHEMBL14506652 | 0.86 | PIK3CA (0.85) | MAPK1PIK3CAMAPK8MAPK9MAPK10 | |
| SCHEMBL14506608 | 0.86 | MAPK1 (1.00) | MAPK1PIK3CAMAPK8MAPK9MAPK10 | |
| SCHEMBL4342227 | 0.86 | MAPK1 (0.84) | MAPK1PIK3CAMAPK8MAPK9MAPK10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1962854-B1 | PYRIDOPYRAZINE DERIVATIVES AND USE THEREOF AS MODULATORS OF THE SIGNAL TRANSDUCTION PATHS | TERNA ZENTARIS GMBH (DE) | 2015-05-06 | — | — | EP | claimed |
| US-20090275534-A1 | NOVEL PYRIDOPYRAZINE DERIVATIVES, PROCESS OF MANUFACTURING AND USES THEREOF | ZENTARIS GMBH (DE) | 2009-11-05 | — | — | US | claimed |
| EP-1990342-A1 | Pyridopyrazine Derivatives, Process of Manufacturing and Uses thereof | AEterna Zentaris GmbH (DE) | 2008-11-12 | — | — | EP | claimed |
| EP-1962854-A2 | PYRIDOPYRAZINE DERIVATIVES AND USE THEREOF AS MODULATORS OF THE SIGNAL TRANSDUCTION PATHS | AEterna Zentaris GmbH (DE) | 2008-09-03 | — | — | EP | claimed |
| WO-2007079999-A2 | PYRIDOPYRAZINE DERIVATIVES AND USE THEREOF AS MODULATORS OF THE SIGNAL TRANSDUCTION PATHS | ÆTERNA ZENTARIS GMBH (DE) | 2007-07-19 | — | — | WO | claimed |
| EP-1962854-B1 | PYRIDOPYRAZINE DERIVATIVES AND USE THEREOF AS MODULATORS OF THE SIGNAL TRANSDUCTION PATHS | TERNA ZENTARIS GMBH (DE) | 2015-05-06 | — | — | EP | disclosed |
| US-8937068-B2 | Pyridopyrazine derivatives and their use | ZENTARIS GMBH (DE) | 2015-01-20 | — | — | US | disclosed |
| US-8937068-B2 | Pyridopyrazine derivatives and their use | ZENTARIS GMBH (DE) | 2015-01-20 | — | — | US | disclosed |
| US-8604196-B2 | Modulating signal transduction pathways with 1-ethyl-3-[3-(1-methyl-1H-pyrazol-4-yl)-pyrido[2.3-B]pyrazine-6-yl]thiourea | AETERNA ZENTARIS GMBH (DE) | 2013-12-10 | — | — | US | disclosed |
| US-8536332-B2 | Modulating signal transduction pathways with substituted pyridol [2,3-b] pyrazines | AETERNA ZENTARIS GMBH (DE) | 2013-09-17 | — | — | US | disclosed |
| US-8536332-B2 | Modulating signal transduction pathways with substituted pyridol [2,3-b] pyrazines | AETERNA ZENTARIS GMBH (DE) | 2013-09-17 | — | — | US | disclosed |
| US-8507486-B2 | Pyridopyrazine derivatives, process of manufacturing and uses thereof | AETERNA ZENTARIS GMBH (DE) | 2013-08-13 | — | — | US | disclosed |
| US-20090275534-A1 | NOVEL PYRIDOPYRAZINE DERIVATIVES, PROCESS OF MANUFACTURING AND USES THEREOF | ZENTARIS GMBH (DE) | 2009-11-05 | — | — | US | disclosed |
| WO-2008138878-A2 | NOVEL PYRIDOPYRAZINE DERIVATIVES, PROCESS OF MANUFACTURING AND USES THEREOF | ÆTERNA ZENTARIS GMBH (DE) | 2008-11-20 | — | — | WO | disclosed |
| EP-1990342-A1 | Pyridopyrazine Derivatives, Process of Manufacturing and Uses thereof | AEterna Zentaris GmbH (DE) | 2008-11-12 | — | — | EP | disclosed |
| EP-1990342-A1 | Pyridopyrazine Derivatives, Process of Manufacturing and Uses thereof | AEterna Zentaris GmbH (DE) | 2008-11-12 | — | — | EP | disclosed |
| EP-1962854-A2 | PYRIDOPYRAZINE DERIVATIVES AND USE THEREOF AS MODULATORS OF THE SIGNAL TRANSDUCTION PATHS | AEterna Zentaris GmbH (DE) | 2008-09-03 | — | — | EP | disclosed |
| WO-2007079999-A2 | PYRIDOPYRAZINE DERIVATIVES AND USE THEREOF AS MODULATORS OF THE SIGNAL TRANSDUCTION PATHS | ÆTERNA ZENTARIS GMBH (DE) | 2007-07-19 | — | — | WO | disclosed |
| US-20070123494-A1 | PYRIDOPYRAZINE DERIVATIVES AND THEIR USE | ZENTARIS GMBH (DE) | 2007-05-31 | — | — | US | disclosed |
| US-20070123494-A1 | PYRIDOPYRAZINE DERIVATIVES AND THEIR USE | ZENTARIS GMBH (DE) | 2007-05-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090275534-A1 | NOVEL PYRIDOPYRAZINE DERIVATIVES, PROCESS OF MANUFACTURING AND USES THEREOF | PNPO, PDXK, MKI67 | MAPK1 460/4885PIK3CA 537/4885MAPK8 1399/4885 |
| US-20070123494-A1 | PYRIDOPYRAZINE DERIVATIVES AND THEIR USE | PLPBP, PDXK, MAP4K2 | MAPK1 58/4885PIK3CA 866/4885MAPK8 116/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.